Sacituzumab Govitecan-hziy

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

Solid TumorEndometrial CancerMetastatic Urothelial CancerThymoma

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

1

Sacituzumab Govitecan-hziy

Gilead

Phase 3

12

Yervoy

Bristol-Myers Squibb

Preclinical

33

Fludara

Sanofi

Preclinical

14

DATROWAY

Daiichi Sankyo

Preclinical

15

Navmi

SSummit Therapeutics

Preclinical

16

Tulmimetostat

Novartis

Preclinical

17

Soc

Pfizer

Preclinical

18

SAR445877

Sanofi

Preclinical

19

IN10018

IInxMed (Shanghai) Co., Ltd.

Preclinical

110

Cadonilimab

SShanghai Pharmaceuticals Holding Co., Ltd

Preclinical

1Show 26 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Thymoma1 trial

A Phase II Parallel Arm Study of SACITUZUMAB GOVITECAN-HZIY in Patients With Advanced Thymoma and Thymic Carcinoma

Recruiting·GGeorgetown University·Phase 2·NCT06248515·18 enrolled

Non-Small Cell Lung Cancer1 trial

An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations

Active, not recruiting·Gilead·Phase 2·NCT05186974·193 enrolled

Triple-Negative Breast Cancer1 trial

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

Recruiting·Gilead·Phase 3·NCT05633654·1,514 enrolled

Metastatic Urothelial Cancer1 trial

A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer

Active, not recruiting·Gilead·Phase 2·NCT03547973·502 enrolled

Endometrial Cancer1 trial

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

Active, not recruiting·Gilead·Phase 3·NCT06486441·640 enrolled

2 more indications

Solid Malignancies1 trial

A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Subjects With Solid Malignancies

Terminated·Gilead·Phase 1·NCT05006794·37 enrolled

Solid Tumor1 trial

A Phase 1/2 Open-Label Study of Sacituzumab Govitecan in Japanese Patients With Advanced Solid Tumors (ASCENT-J02)

Active, not recruiting·Gilead·Preclinical·NCT05101096·135 enrolled

Details

Drug Info

Related News